Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles and gels in drug delivery: State-of-the-art and future perspectives

Handbook of Hydrogels: Properties, Preparation & Applications

Volumn , Issue , 2011, Pages 449-484

  Alvarez Lorenzo, Carmen ^a   Concheiro, Angel ^a   Sosnik, Alejandro ^b,c  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78149373490     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (227)

1. Lindenberg, M., Kopp, S. & Dressman, J.B. (2004) Classification of orally administered drug on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system, Eur J Pharm Biopharm, 58, 265-278.
2. Ku, M. S. (2008) Use of the biopharmaceutical classification system in early drug development, AAPS J, 10, 208-212.
3. Cook, J., Addicks, W., & Wu, Y.R. (2008) Application of the Biopharmaceutical Classification System in clinical drug development-An industrial view, AAPS J, 10, 306-310.
4. Amidon, G.L., Lennernäs, H., Shah, V.P. & Crison J.R. (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm Res, 12, 413-420.
5. Lipinski, C. (2002) Poor aqueous solubility-an industry wide problem in drug delivery, Am Pharm Rev, 5, 82-85.
6. Loftsson, T., Brewster, M.E. & Másson, M. (2004) Role of cyclodextrins in improving oral drug delivery, Am J Drug Deliv, 2, 261-275.
7. Benet, L.Z., Amidon, G.L., Barends, D.M., Lennernas, H., Polli, J.E., Shah, V.P., Stavchansky, S.A. & Yu, X.L. (2008) The use of BDDCS in classifying the permeability of marketed drugs, Pharm Res, 25, 483-488.
8. Kataoka, K., Harada, A. & Nagasaki, Y. (2001) Block copolymer micelles for drug delivery: design, characterization and biological significance, Adv Drug Deliv Rev, 47, 113-131.
9. Croy, S.R. & Kwon, G.S. (2006) Polymeric Micelles for drug delivery, Curr Pharm Design, 12, 4669-4684.
10. Barratt, G. (2003) Colloidal drug carriers: achievements and perspectives, Cell Mol Life Sci, 60, 21-37.
11. Moghimi, S.M., Muir, I.S., Illum, L., Davis, S.S. & Kolb-Bachofen, V. (1993) Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum, Biochim Biophys Acta, 1179, 157-165.
12. Alexandridis, P. & Hatton, T.A. (1995) Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer surfactants in aqueous solutions and interfaces: thermodynamics, structure, dynamics and modeling, Colloids Surf A, 96, 1-46.
13. Chiappetta, D.A. & Sosnik A. (2007) Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: Improved hydrosolubility, stability and bioavailability of drugs, Eur J Pharm Biopharm, 66, 303-317.
14. Alvarez-Lorenzo, C. & Concheiro, A. (2008) Intelligent drug delivery systems: Polymeric micelles and hydrogels, Mini-Rev Med Chem, 11, 1065-1074.
15. Cao, Y., Rodriguez, A., Vacanti, M., Ibarra, C., Arevalo, C. & Vacanti, C.A. (1998) Comparative study of the use of poly(glycolic acid), calcium alginate and pluronics in the engineering of autologous porcine cartilage, J Biomater Sci Polym Ed, 9, 475-487.
16. Saim, A.B., Cao, Y., Weng, Y., Chang, C.N., Vacanti, M.A., Vacanti, C.A. & Eavy, R.D. (2000) Engineering autogenous cartilage in the shape of a helix using an injectable hydrogel scaffold, Laryngoscope, 110, 1694-1697.
17. Reeve, L. (1997) The poloxamers: their chemistry and medical applications, in: A. Domb, Y. Kost & D. Wiseman (Eds.), Handbook of Biodegradble Polymers (Drug Targeting and Delivery, vol. 7), Harwood Academic Publishers, London, Great Britain, pp. 231-249.
18. Pec, E.A., Wout, Z.G. & Johnston, T.P. (1992) Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat, J Pharm Sci, 81, 626-630.
19. Grindel, J.M., Jaworski, T., Piraner, O., Emanuele, R.M. & Balasubramanian, M. (2002) Distribution, metabolism, and excretion of a novel surface-active agent, purified poloxamer 188, in rats, dogs, and humans, J Pharm Sci, 91, 1936-1947.
20. Bromberg, L.E. & Ron, E.S. (1998) Temperature-responsive gels and thermogelling polymer matrices for protein and peptide delivery, Adv Drug Del Rev, 31, 197-221.
21. Kabanov, A.V. & Alkhov, V.Yu. (2002) Pluronic® block copolymers in drug delivery: From micellar nanocontainers to biological response modifiers, Critical Rev Therap Drug Carrier Syst, 19, 1-72.
22. Kibbe, A.H. (2000) Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, Washington D.C, pp. 386-388.
23. Tonge, S., Jones, L., Goodall, S. & Tighe, B. (2001) The ex vivo wettability of soft contact lenses, Curr Eye Res, 23, 51-59.
24. Subbaraman, L.N., Bayer, S., Gepr, S., Glasier, M.-A., Lorentz, H., Senchyna, M. & Jones, L. (2006) Rewetting drops containing surface active agents improve the clinical performance of silicone hydrogel contact lenses, Optometry Vis Sci, 83, 143-151.
25. Fernandez-Tarrio, M., Alvarez-Lorenzo, C. & Concheiro, A. (2007) Calorimetric approach to Tetronic/water interactions, J Thermal Anal Calorim, 87, 171-178.
26. Attwood, D., Zhou, Z. & Booth, C. (2007) Poly(ethylene oxide) based copolymers: solubilisation capacity and gelation, Expert Opinion Drug Del, 4, 533-546.
27. Gonzalez-Lopez, J., Alvarez-Lorenzo, C., Taboada P., Sosnik, A., Sandez-Macho, I. & Concheiro A. (2008) Self-associative behavior and drug solubilizing ability of poloxamine (Tetronic®) block copolymers, Langmuir, 24, 10688-10697.
28. Oh, K.T., Bronich, T.K. & Kabanov, A.V. (2004) Micellar formulations for drug delivery based on mixtures of hydrophobic and hydrophilic Pluronic block copolymers, J Control Rel, 94, 411-422.
29. Vadnere, M., Amidon, G.L., Lindenbaum, S. & Haslam, J.L. (1984) Thermodynamic studies on gel-sol transition of some Pluronic polyols, Int J Pharm, 22, 207-218.
30. Mortensen, K. & Pedersen, J.S. (1993) Structural study on the micelle formation of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock-copolymer in aqueous solution, Macromolecules, 26, 805-812.
31. Schmolka, I.R. (1972) Artificial skin I. Preparation and properties of pluronic F-127 gels for treatment of burns, J Biomed Mater Res, 6, 571-582.
32. Krezanoski, J.Z. (1980) Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes, U.S. Patent 4,188,373.
33. Homicz, M.R. & Watson, D. (2004) Review of Injectable materials for soft tissue augmentation. Facial Plast Surg, 20, 21-29.
34. Dong, J., Chowdhry, B.Z. & Leharne, S.A. (2003) Surface activity of poloxamines at the interfaces between air-water and hexane-water, Colloids and Surfaces A: Physicochem Eng Aspects, 212, 9-17.
35. Sosnik, A. & Sefton, M.V. (2006) Methylation of poloxamine for enhanced cell adhesion, Biomacromolecules, 7, 331-338.
36. Sosnik, A. & Sefton, M.V. (2005) Semi-synthetic collagen/poloxamine matrices for Tissue Engineering applications, Biomaterials, 26, 7425-7435.
37. Paterson, I.F., Chowdhry, B.Z. & Leharne, S.A. (1999) Investigations of naphthalene solubilization in aqueous solutions of ethylene oxide-b-propylene pxide-b-ethylene oxide copolymers, Langmuir, 15, 6187-6194.
38. Dong, J., Armstrong, J., Chowdry, B.Z. & Leharne, S.A. (2004) Thermodynamic modelling of the effect of pH upon aggregation transitions in aqueous solutions of the poloxamine, T701, Therm Acta, 417, 201-206.
39. Hurter, P.N. & Hatton, T.A. (1992) Solubilization of polycyclic aromatic hydrocarbons by poly(ethylene oxide-propylene oxide) block copolymer micelles: Effects of polymer structure, Langmuir, 8, 1291-1299.
40. Dong, J., Chowdry, B.Z. & Leharne, S.A. (2004) Solubilisation of polyaromatic hydrocarbons in aqueous solutions of poloxamine T803, Colloids and Surfaces A: Physicochem Eng Aspects, 246, 91-98.
41. Oh, K.T., Bronich, T.K. & Kabanov, A.V. (2004) Micellar formulations for drug delivery based on mixtures of hydrophobic and hydrophilic Pluronic® block copolymers, J Control Rel, 94, 411-422.
42. Batrakova, E.V., Kelly, D.L., Li, S., Li, Y., Yang, Z., Xiao, L., Alakhova, D.Y., Sherman, S., Alakhov, V.Y. & Kabanov, A.V. (2006) Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: Pluronic P85, Mol Pharm, 3, 113-123.
43. Witt, K.A., Huber, J.D., Egleton, R.D. & Davis, T.P. (2002) Pluronic P85 copolymer enhances opioid peptide analgesia, J Pharm Exp Therap, 303, 760-767.
44. Alvarez-Lorenzo, C., Gonzalez-Lopez, J., Fernandez-Tarrio, M., Sandez-Macho, I. & Concheiro, A., (2007) Tetronic micellization, gelation and drug solubilization: Influence of pH and ionic strength, Eur J Pharm Biopharm, 66, 244-252.
45. Sosnik, A., Chiappetta, D.A. & Hocht, C., Aqueous pharmaceutical compositions for the oral administration of antiretroviral agents, Patent application P090102571, National Institute of Industrial Property (INPI), Argentina.
46. Chiappetta, D.A., Degrossi, J., Teves, S., D'Aquino, M., Bregni C. & Sosnik, A. (2008) Triclosan-loaded poloxamine micelles for enhanced antibacterial activity against biofilm, Eur J Pharm Biopharm, 69, 535-545.
47. Munshi, N., Rapoport, N. & Pitt, W.G. (1997) Ultrasonic activated drug delivery from Pluronic P-105 micelles, Cancer Lett., 118, 13-19.
48. Rapoport, N., Herron, J.N., Pitt, W.G. & Pitina, L. (1999) Micellar delivery of doxorubicin and its paramagnetic analog, ruboxyl, to HL-60 cells: effect of micelle structure and ultrasound on the intracellular drug uptake, J Control Rel, 58, 153-162.
49. Husseini, G.A., El-Fayoumi, R.I., O'Neill, K.L, Rapoport, N.Y. & Pitt, W.G. (2000) DNA damage induced by micellar-delivered doxorubicin and ultrasound: comet assay study, Cancer Lett, 154, 211-216.
50. Husseini, G.A., Rapoport, N.Y., Christensen, D.A., Pruitt, J.D. & Pitt, W.G. (2002) Kinetics of ultrasonic release of doxorubicin from pluronic P105 micelles, Colloids Surf. B Biointerfaces, 24, 253-264.
51. Rapoport, N. (2004) Combined cancer therapy by micellar-encapsulated drug and ultrasound, Int J Pharm, 277, 155-162.
52. Gao, Z.-G., Fain, H.D. & Rapoport, N. (2005) Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound, J Control Rel, 102, 203-222.
53. Stevenson-Abouelnasr, D., Husseini, G.A & Pitt, W.G. (2007) Further investigation of the mechanism of doxorubicin release from P105 micelles using kinetic models, Colloids Surf. B Biointerfaces, 55, 59-66.
54. Rapoport, N., Gao, Z. & Kennedy, A. (2007) Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy, JNCI, 99, 1095-1106.
55. Ryu, J.-M., Chung, S.-J., Lee, M.-H., Kim, C.-K. & Kim, C.-H. (1999) Increased bioavailability of propranolol in rats by retaining thermally gelling liquid suppositories in the rectum, J Control Rel, 59, 163-172.
56. Dumortier, G., Groissord, J.L., Zuber, M., Couarraze, G. & Chaumeil, J.C. (1991) Rheological study of a thermoreversible morphine gel, Drug Dev Ind Pharm, 17, 1255-1265.
57. Barichello, J.M., Morishita, M., Takayama, K., Chiba, Y., Tokiwa, S. & Nagai, T. (1999) Enhanced rectal absorption of insulin-loaded Pluronic® F-127 gels containing unsaturated fatty acids, Int J Pharm, 183, 125-132.
58. Barichello, J.M, Morishita, M., Takayama, K. & Nagai, T. (1999) Absorption of insulin from Pluronic F-127 gels following subcutaneous administration in rats, Int J Pharm, 184, 189-198.
59. Morishita, M., Barichello, J.M., Takayama, K., Chiba, Y., Tokiwa, S. & Nagai, T. (2001) Pluronic® F-127 gels incorporating highly purified unsaturated fatty acids for buccal delivery of insulin, Int J Pharm, 212, 289-293.
60. Lagarce, F., Faisant, N., Desfontis, J.-C., Marescaux, L., Gautier, F., Richard, J., Menei, P. & Benoit, J.-P. (2005) Baclofen-loaded microspheres in gel suspensions for intrathecal drug delivery: In vitro and in vivo evaluation, Eur J Pharm Biopharm, 61, 171-180.
61. Csaba,N., Caamaño, P., Sánchez, A., Domínguez, F. & Alonso, M.J. (2005) PLGA:poloxamer and PLGA:poloxamine blend nanoparticles: New carriers for gene delivery, Biomacromolecules, 6, 271-278.
62. Csaba, N., Sánchez, A. & Alonso, M.J. (2006) PLGA:poloxamer and PLGA:poloxamine blend nanostructures as carriers for nasal gene delivery. J Control Rel, 113, 164-172.
63. Santander-Ortega, M.J., Csaba, N., Alonso, M.J., Ortega-Vinuesa, J.L. & Bastos-González, D. (2007) Stability and physicochemical characteristics of PLGA, PLGA:poloxamer and PLGA:poloxamine blend nanoparticles: A comparative study. Colloids and Surfaces A: Physicochemical and Eng Aspects, 296, 132-140.
64. Fang, J.-Y., Hsu, S.-H., Leu, Y.-L. & Hu, J.-W. (2009) Delivery of cisplatin from Pluronic copolymer system: Liposome inclusion and alginate coupling, J Biomater Sci Polym Edn, 20, 1031-1047.
65. Alvarez-Lorenzo, C., Gonzalez-Lopez, J., Fernandez-Tarrio, M., Sandez-Macho, I. & Concheiro, A. (2007) Tetronic micellization, gelation and drug solubilization: Influence of pH and ionic strength, Eur J Pharm Biopharm, 66, 244-252.
66. Rath, W., Dennemark, N. & Gödicke, H.-D. (1985) Preoperative cervical priming by intracervical application of a new sulprostone gel, Contraception, 31, 207-216.
67. Rassing, J. (1985) A new ultrasonic differential method for measuring diffusion coefficients of drugs inside small gel samples. Application to the diffusion of lidocaine hydrochloride and lidocaine base inside a 25% Pluronic® F-127 gel, J Control Rel, 1, 169-175.
68. Saettone, M.F., Giannaccini, B., Delmonte, G., Campigli, V., Tota, G. & La Marca, F. (1988) Solubilization of tropicamide by poloxamers: physicochemical data and activity data in rabbits and humans, Int J Pharm, 43, 67-76.
69. Carmignani, C., Rossi, S., Saettone, M.F. & Burgalassi, S. (2002) Ophthalmic vehicles containing polymer-solubilized tropicamide: "in vitro/in vivo" evaluation, Drug Dev Ind Pharm, 28, 101-105.
70. Law, T.K., Florence, A.T. & Whateley, T.L. (1986) Some chemically modified poloxamer hydrogels: controlled release of prostaglandin-E2 and testosterone, Int J Pharm, 33, 65-69.
71. Kabanov, A.V., Ckekhonin, V.P., Alakhov, V., Batrakova, E.V., Lebedev, A.S., Melik-Nubarov, N.S., Arzhakov, S.A., Levashov, A.V., Morozov, G.V., Severin, E.S. & Kabanov, V.A. (1989) The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles, FEB Lett, 258, 343-345.
72. Saito, Y., Kondo, Y., Abe, M. & Sato, T. (1994) Solubilization behavior of estriol in an aqueous solution of pluronic L-64 as a function of concentration and temperature, Chem Pharm Bull, 42, 1348-1350.
73. Saito, Y. & Sato, T. (1998) Effects of inorganic salts on solubilization of estriol in an aqueous solution of poly(ethylene oxide)/poly(propylene oxide)/poly(ethylene oxide) triblock copolymer, Drug Dev Ind Pharm, 24, 385-388.
74. Khidr, S.H. (1994) Effect of block copolymers on the dissolution of some waterinsoluble drugs. Part-1. Nifedipine-pluronic F127 solid dispersions system, Bull Pharm Sci, 17, 81-86.
75. Gust, R., Bernhardt, G., Spruss, T., Krauser, R., Koch, M., Schonenberger, H., Bauer, K.-H., Schertl, S. & Lu, Z. (1995) Development of a parenterally administrable hydrosol preparation of the 'third generation platinum complex' [(±)-1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II). Part 1. Preparation and studies on the stability and antitumor activity, Archiv Pharmazie, 328, 645-653.
76. Taguchi, J., Abe, J., Okazaki, H., Ochiai, M., Ohno, M., Takuwa, Y. & Kurokawa, K. (1993) Angiotensin converting enzyme inhibitors or DuP753 prevent neointimal formation following balloon injury with single topical or multiple systemic application, Biochem Biophys Res Comm, 196, 969-974.
77. Molpeceres, J., Guzmán, M., Bustamante, P. & Aberturas, M.R. (1996) Exothermicendothermic heat of solution shift of cyclosporin A related to poloxamer 188 behavior in aqueous solutions, Int J Pharm, 130, 75-81.
78. Bonina, F.P., & Montenegro, L. (1994) Vehicle effects on in vitro heparin release and skin penetration from different gels, Int J Pharm, 102, 19-24.
79. Faulkner, D.M., Sutton, S.T., Hesford, J.D., Faulkner, B.C., Major, D.A., Hellewell, T.B., Laughon, M.M., Rodeheaver, G.T.,& Edlich, R.F. (1997) A new stable pluronic® F68 gel carrier for antibiotics in contaminated wound treatment, Am J Emerg Med, 15, 20-24.
80. Batrakova, E.V., Dorodnych, T.Y., Klinskii, E.Y., Kliushnenkova, E.N., Shemchukova, O.B., Goncharova, O.N., Arjakov, S.A., Alakhov, V.Y. & Kabanov, A.V. (1996) Anthracycline antibiotics non-covalently incorporated into the block copolymer mivcelles: in vivo evaluation of anticancer activity, Br J Cancer, 74, 1545-1552.
81. Suh, H. & Jun, H.W. (1996) Physicochemical and release studies of naproxen in poloxamer gels, Int J Pharm, 129, 13-20.
82. Suh, H., Jun, W., Dziminaskl, M.T. & Lu, G.W. (1997) Pharmacokinetic and local tissue disposition studies of naproxen following topical and systemic administration in dogs and rats, Biopharm Drug Dispos, 18, 623-633.
83. McNealy, T.L., Trojan, L., Knoll, T., Alken, P. & Michel, M.S. (2004) Micelle delivery of doxorubicin increases cytotoxicity to prostate carcinoma cells, Urol Res, 32, 255-260.
84. Batrakova, E.V., Kelly, D.L., Li, S., Li, Y., Yang, Z., Xiao, L., Alakhova, D.Y., Sherman, S., Alakhov, V.Y. & Kabanov, A.V. (2006) Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: Pluronic P85, Mol Pharm, 3, 113-123.
85. Miller, S.C. & Donovan, M.D. (1982) Effect of poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits, Int J Pharm, 12, 147-152.
86. Desai, S.D. & Blanchard, J. (1998) In vitro evaluation of pluronic F127-based controlled-release ocular delivery systems for pilocarpine, J Pharm Sci, 87, 226-230.
87. Desai, S.D. & Blanchard, J. (1998) Evaluation of Pluronic F127-based sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model, J Pharm Sci, 87, 1190-1195.
88. Hammad, M.A. & Muller, B.W. (1998) Solubility and stability of clonazepam in mixed micelles, Int J Pharm, 169, 55-64.
89. Pandit, N.K. & Wang, D. (1998) Salt effects on the diffusion and release rate of propranolol from poloxamer 407 gels, Int J Pharm, 167, 183-189.
90. Ryu, J.-M., Chung, S.-J., Lee, M.-H., Kim, C.-K. & Kim, C.-H. (1999) Increased bioavailability of propranolol in rats by retaining thermally gelling liquid suppositories in the rectum, J Control Rel, 59, 163-172.
91. Veyries, M.L., Couarraze, G., Geiger, S., Agnely, F., Massias, L., Kunzli, B., Faurisson, F. & Rouveix, V. (1999) Controlled release of vancomycin from Poloxamer 407 gels, Int J Pharm, 192, 183-193.
92. Lee, S.H., Lee, J.E., Baek, W.Y. & Lim, J.O. (2004) Regional delivery of vancomycin using pluronic F-127 to inhibit methicillin resistant Staphylococcus aureus (MRSA) growth in chronic otitis media in vitro and in vivo, J Control Rel, 96, 1-7.
93. Mohamed, F.A. (1995) Transdermal delivery of diclofenac sodium from Pluronic and other conventional formulations, S.T.P. Pharma Pratiques, 5, 456-460.
94. Khalil, E., Najjar, S. & Sallam, A. (2000) Aqueous solubility of diclofenac diethylamine in the presence of pharmaceutical additives: A comparative study with diclofenac sodium, Drug Dev Ind Pharm, 26, 375-381.
95. Park, Y.J., Yong, C.S., Kim, H.M., Rhee, J.D., Oh, Y.K. & Kim, C.K. (2003) Effect of sodium chloride on the release, absorption and safety of diclofenac sodium delivered by poloxamer gel, Int J Pharm, 263, 105-111.
96. El-Kattan, A.F, Asbill, C.S., Kim, N. & Michniak, B.B. (2000) Effect of formulation variables on the percutaneous permeation of ketoprofen from gel formulations, Drug Deliv, 7, 147-153.
97. Takahashi, A., Suzuki, S., Kawasaki, N., Kubo, W., Miyazaki, S., Loebenberg, R., Bachynsky, J. & Attwood, D. (2002) Percutaneous absorption of non-steroidal antiinflammatory drugs from in situ gelling xyloglucan formulations in rats, Int J Pharm, 246, 179-186.
98. Shin, S.-C., Cho, C.-W. & Oh, I.-J. (2000) Enhanced efficacy by percutaneous absorption of piroxicam from the poloxamer gel in rats, Int J Pharm, 193, 213-218.
99. Dimitrova, E., Bogdanova, S., Mitcheva, M., Tanev, I. & Minkov, E. (2000) Development of model aqueous ophthalmic solution of indomethacin, Drug Dev Ind Pharm, 26, 1297-1301.
100. Scherlund, M., Brodin, A. & Malmsten, M. (2000) Micellization and gelation in block copolymer systems containing local anesthetics, Int J Pharm, 211, 37-49.
101. Shin, S.-C. & Kim, J.-Y. (2000) Enhanced permeation of triamcinolone acetonide through the buccal mucosa, Eur J Pharm Biopharm, 50, 217-220.
102. Batrakova, E.V., Miller, D.W., Li, S., Alakhov, V.Y., Kabanov, A.V. & Elmquist, W.F. (2001) Pluronic P85 Enhances the delivery of digoxin to the brain: In Vitro and in Vivo studies, J Pharm Exp Therap, 296, 551-557.
103. Rekatas, C.J., Mai, S.-M., Crothers, M., Quinn, M., Collett, J.H., Attwood, D., Heatley, F., Martini, L. & Booth, C. (2001) The effect of hydrophobe chemical structure and chain length on the solubilization of griseofulvin in aqueous micellar solutions of block copoly(oxyalkylene)s, Phys Chem Chem Phys, 3, 4769-4773.
104. Wenzel, J.G.W., Sree Balaji, K.S., Koushik, K., Navarre, C., Duran, S.H., Hardin Rahe, C. & Kompell, U.B. (2002) Pluronic® F127 gel formulations of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle, J Control Rel, 85, 51-59.
105. El-Kamel, A.H. (2002) In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate, Int J Pharm, 241, 47-55.
106. Stamatialisa, D.F., Rolevinka, H.H.M. & Koops, G.H. (2006) Transdermal timolol delivery from a Pluronic gel, J Control Rel, 116, e53-355.
107. Hioka, N., Chowdhary, R.K., Chansarkar, N., Delmarre, D., Sternberg, E. & Dolphin, D. (2002) Studies of a benzoporphyrin derivative with Pluronics, Can J Chem, 80, 1321-1326.
108. Chowdhary, R.K., Chansarkar, N., Sharif, I., Hioka, N. & Dolphin, D. (2003) Formulation of benzoporphyrin derivatives in Pluronics, Photochem Photobiol, 77, 299-303.
109. Barreiro-Iglesias, R., Alvarez-Lorenzo, C. & Concheiro, A. (2003) Controlled release of estradiol solubilized in carbopol/surfactant aggregates, J Control Rel, 93, 319-330.
110. Momot, K.I., Kuchel, P.W., Deo, P. & Whittaker, D. (2003) NMR study of the association of propofol with nonionic surfactants, Langmuir, 19, 2088-2095.
111. Baker, M.T. & Naguib, M. (2005) Propofol: The challenges of formulation, Anesthesiology, 103, 860-876.
112. Gao, Z., Fain, H.D. & Rapoport, N. (2004) Ultrasound-enhanced tumor targeting of polymeric micellar drug carriers, Mol Pharm, 1, 317-330.
113. Barreiro Iglesias, R., Bromberg, L., Temchenko, M., Hatton, T.A., Concheiro, A. & Alvarez-Lorenzo, C. (2004) Solubilization and stabilization of camptothecin in micellar solutions of pluronic-g-poly(acrylic acid) copolymers, J Control Rel, 97, 537-549.
114. Sezgin, Z., Yüksel, N. & Baykara, T. (2006) Preparation and characterization of polymeric micelles for solubilization of poorly soluble anticancer drugs, Eur J Pharm Biopharm, 64, 261-268.
115. Alakhov, V., Pietrzynski, G., Patel, K., Kabanov, A., Bromberg, L. & Hatton, T.A. (2004) Pluronic block copolymers and Pluronic poly(acrylic acid) microgels in oral delivery of megestrol acetate, J Pharm Pharmacol, 56, 1233-1241.
116. Croy, S.R. & Kwon, G.S. (2004) The effects of Pluronic block copolymers on the aggregation state of nystatin, J Control Rel, 95, 161-171.
117. Yong, C.S., Lee, M.-K., Park, Y.-J., Kong, K.-H., Xuan, J.J., Kim, J.-H., Kim, J.-A., Seok, W., Han, S.S., Rhee, J.-D., Kim, J.O., Yang, C.H., Kim, C.-K. & Choi, H.-G. (2005) Enhanced oral bioavailability of ibuprofen in rats by poloxamer gel using poloxamer 188 and menthol, Drug Dev Ind Pharm, 31, 615-622.
118. Han, L.-M., Guo, J., Zhang, L.-J., Wang, Q.-S. & Fang, X.-L. (2006) Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123, Acta Pharmacol Sin, 27, 747-753.
119. Sezgin, Z., Yuksel, N. & Baykara T. (2007) Investigation of pluronic and PEG-PE micelles as carriers of meso-tetraphenyl porphine for oral administration, Int J Pharm, 332, 161-167.
120. Ahuja, N., Katare, O.P. & Singh, B. (2007) Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using watersoluble carriers, Eur J Pharm Biopharm, 65, 26-38.
121. Abd El-Bary, A., Foda, N. & Tayel, S. (1991) Bioavailability of glibenclamide from nasal delivery systems, Pharm Industrie, 53, 1151-1155.
122. Johnston, T.P., Punjabi, M.A. & Froelich, C.J. (1992) Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice, Pharm Res, 9, 425-434.
123. Edelman, E.R., Simons, M., Sirois, M.G. & Rosenberg, R.D. (1995) c-myc in vasculoproliferative disease. Circ Res, 76, 176-182.
124. DiBiase, M.D. & Rhodes, C.T. (1996) Formulation and evaluation of epidermal growth factor in Pluronic F-127 gel, Drug Dev Ind Pharm, 22, 823-831.
125. Wong, C.-Y., Wang, D.-P. & Chang, L.-C. (1997) Stability of cefazolin in pluronic F-127 gels, Drug Dev Ind Pharm, 23, 603-605.
126. Gottsauner-Wolf, M., Jang, Y., Lincoff, A.M., Cohen, J.L., Labhasetwar, V., Poptic, E.J., Forudi, F., Guzman, L.A., Dicorleto, P.E., Levy, R.J., Topol, E.J. & Ellis, S.G. (1997) Influence of local delivery of the protein tyrosine kinase receptor inhibitor tyrphostin-47 on smooth-muscle cell proliferation in a rat carotid balloon-injury model, Am Heart J, 133, 329-334.
127. Castier, Y., Chemla, E., Nierat, J., Heudes, D., Vasseur, M.A., Rajnoch, Ch., Bruneval, P., Carpentier, A. & Fabiani, J.N. (1998) The activity of c-myb antisense oligonucleotide to prevent intimal hyperplasia is nonspecific, J Carciovasc Surg, 39, 1-7.
128. Blonder, J.M., Robinson, S.N., Chavez, J.M., Pisarev, V.M., Sang, H.K., Hatcher, L., Munger, C., Harrington, K., Lin, B., Talmadge, J.E. & Rosenthal, G.J. (2001) G-CSF formulated in a pluronic-based matrix shows extended pharmacokinetics and enhanced hematopoeitic activity, Blood, 98, 297a.
129. Bourre, L., Thibaut, S., Briffaud, A., Lajat, Y., & Patrice, T. (2002) Potential efficacy of a delta 5-aminolevulinic acid thermosetting gel formulation for use in photodynamic therapy of lesions of the gastrointestinal tract, Pharmacol Res, 45, 159-165.
130. Fulton, G.J., Davies, M.G., Barber, L., Gray, J.L., Svendsen, E. & Hagen, P.O. (1998) Local effects of nitric oxide supplementation and suppression in the development of intimal hyperplasia in experimental vein grafts, Eur J Vasc Endovasc Surg, 15, 279-289.
131. Shishido, S.M., Seabra, A.B., Loh, W. & De Oliveira, M.G. (2003) Thermal and photochemical nitric oxide release from S-nitrosothiols incorporated in Pluronic F127 gel: Potential uses for local and controlled nitric oxide release, Biomaterials, 24, 3543-3553.
132. Amadeu, T.P., Seabra, A.B., de Oliveira, M.G., & Monte-Alto-Costa, A. (2008) Nitric oxide donor improves healing if applied on inflammatory and proliferative phase, J Surg Res, 149, 84-93.
133. Pisal, S.S., Paradkar, A.R., Mahadik, K.R. & Kadam, S.S. (2004) Pluronic gels for nasal delivery of Vitamin B12. Part I: Preformulation study, Int J Pharm, 270, 37-45.
134. Fujinaga, K., Onoda, K., Yamamoto, K., Imanaka-Yoshida, K., Takao, M., Shimono, T., Shimpo, H., Yoshida, T., & Yada, I. (2004) Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts, J Thoracic Cardiovasc Surg, 128, 357-363.
135. Attia, M.A., El-Gibalya, I., Shaltoutb, S.E. & Fetih, G.N. (2004) Transbuccal permeation, anti-inflammatory activity and clinical efficacy of piroxicam formulated in different gels, Int J Pharm, 276, 11-28.
136. Coeshott, C.M., Smithson, S.L., Verderber, E., Samaniego, A., Blonder, J.M., Rosenthal, G.J. & Westerink, M.A.J. (2004) Pluronic® F127-based systemic vaccine delivery systems, Vaccine, 22, 2396-2405.
137. García-Trapero, J., Carceller, F., Dujovny, M. & Cuevas, P. (2004) Perivascular delivery of neomycin inhibits the activation of NF-κB and MAPK pathways, and pre\, 26, 816-824.
138. Sinn, P.L., Shah, A.J., Donovan, M.D. & McCray Jr., P.B. (2005) Viscoelastic gel formulations enhance airway epithelial gene transfer with viral vectors, Am J Resp Cell Mol Biol, 32, 404-410.
139. Schachner, T., Zou, Y., Oberhuber, A., Tzankov, A., Mairinger, T., Laufer, G., & Bonatti, J.O. (2004) Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts, Ann Thoracic Surg, 77, 1580-1585.
140. Schachner, T., Oberhuber, A., Zou, Y., Tzankov, A., Ott, H., Laufer, G., & Bonatti, J. (2005) Rapamycin treatment is associated with an increased apoptosis rate in experimental vein grafts, Eur J Cardio-Thoracic Surg, 27, 302-306.
141. Strappe, P.M., Hampton, D.W., Cachon-Gonzalez, B., Fawcett, J.W. & Lever, A. (2005) Delivery of a lentiviral vector in a Pluronic F127 gel to cells of the central nervous system, Eur J Pharm Biopharm, 61, 126-133.
142. Weaver, M., Liu, J., Pimentel, D., Reddy, D.J., Harding, P., Peterson, E.L. & Pagano, P.J. (2006) Adventitial delivery of dominant-negative p67phox attenuates neointimal hyperplasia of the rat carotid artery, Am J Physiol-Heart Circ Physiol, 290, H1933-H1941.
143. Cronin, M., Anderson, P.N., Green, C.R. & Becker, D.L. (2006) Antisense delivery and protein knockdown within the intact central nervous system, Front Biosci, 11, 2967-2975.
144. Rodriguez-Perez, A.I., Rodriguez-Tenreiro, C., Alvarez-Lorenzo, C., Concheiro, A. & Torres-Labandeira, J.J. (2006) Drug solubilization and delivery from cyclodextrinpluronic aggregates, J Nanosci Nanotech, 6, 3179-3186.
145. Wang, Y., Gao, J.-Q., Li, F., Ri, S.-H. & Liang, W.-Q. (2006) Triblock copolymer Pluronic ®F127 sustains insulin release and reduces initial burst of microspheres-In vitro and in vivo study, Colloid Pol Sci, 285, 233-238.
146. Pluta, J. & Karolewicz, B. (2006) In vitro studies of the properties of thermosensitive systems prepared on Pluronic F-127 as vehicles for methotrexate for delivery to solid tumours, Polimery w Medycynie, 36, 37-53.
147. Liu, Y., Lu, W.-L., Wang, J.-C., Zhang, X., Zhang, H., Wang, X.-Q., Zhou, T.-Y. & Zhang, Q. (2007) Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic® F127 hydrogel for subcutaneous administration: In vitro and in vivo characterization, J Control Rel, 117, 387-395.
148. Bendas, E.R. & Tadros, M.I. (2007) Enhanced transdermal delivery of salbutamol sulfate via ethosomes, AAPS PharmSciTech, 8, Art. 107.
149. Lee, S.-B., Geroski, D.H., Prausnitz, M.R. & Edelhauser, H.F. (2004) Drug delivery through the sclera: Effects of thickness, hydration, and sustained release systems, Exp Eye Res, 78, 599-607.
150. Kikwai, L., Babu, R.J., Prado, R., Kolot, A., Armstrong, C.A., Ansel, J.C. & Singh, M. (2005) In vitro and in vivo evaluation of topical formulations of spantide II, AAPS PharmSciTech, 6, E565-E572.
151. Robinson, S.N., Chavez, J.M., Pisarev, V.M., Mosley, R.L., Rosenthal, G.L., Blonder, J.M. & Talmadge, J.E. (2003) Delivery of Flt3 ligand (Flt3L) using a poloxamer-based formulation increases biological activity in mice, Bone Marrow Transpl, 31, 361-369.
152. Ashour, A.E., Turnquist, H.R., Burns, N., Wang, X., Lin, X., Tremayne, J., Hollingsworth, M.A., Blonder, J.M., Rosenthal, G.J., Talmadge, J.E., Solheim, J.C. (2007) Cancer Biother Radiopharmaceut, 22, 235-238.
153. Li, X.-Y., Zhu, Z.-J. & Cheng, A.-Y. (2008) Characteristics of poloxamer thermosensitive in situ gel of dexamethasone sodium phosphate, Yaoxue Xuebao, 43, 208-213.
154. Lagarce, F., Faisant, N., Desfontis, J.-C., Marescaux, L., Gautier, F., Richard, J., Menei, P. & Benoit, J.-P. (2005) Baclofen-loaded microspheres in gel suspensions for intrathecal drug delivery: In vitro and in vivo evaluation, Eur J Pharm Biopharm, 61, 171-180.
155. Cafaggi, S., Leardi, S. R., Parodi, B., Caviglioli, G. & Bignardi G. (2003) An example of application of a mixture design with constraints to a pharmaceutical formulation, Chemometr Intel Lab Syst, 65, 139-147.
156. Cafaggi, S., Russo, E., Caviglioli, G., Parodi, B., Stefani, R., Sillo, G., Leardi, R. & Bignardi, G. (2008) Poloxamer 407 as a solubilising agent for tolfenamic acid and as a base for a gel formulation, Eur J Pharm Sci, 35, 19-29.
157. Gou, M., Li, X., Dai, M., Gong, C., Wang, X., Xie, X., Deng, H., Chen, L., Zhao, X., Qiana, Z., & Wei, Y. (2008) A novel injectable local hydrophobic drug delivery system: Biodegradable nanoparticles in thermo-sensitive hydrogel, Int J Pharm, 359, 228-233.
158. Spancake, C.W., Mitra, A.K. & Kildsig, D.O. (1991) Kinetics of aspirin hydrolysis in aqueous solutions and gels of poloxamines (Tetronic 1508)-Influence of microenvironment, Int J Pharm, 75, 231-239.
159. Miyazaki, S., Oda, M., Takada, M. & Attwood, D. (1995) Thermally gelling poloxamine synperonic T908 solution as a vehicle for rectal drug delivery, Biol Pharm Bull, 18, 1151-1153.
160. Dumortier, G., Groissord, J.L., Agnely, F. & Chaumeil, J.C. (2006) A review of poloxamer 407 pharmaceutical and pharmacological characteristics, Pharm Res, 23, 2709-2728.
161. Steinleitner, A., Lambert, H., Kazensky, C. & Cantor, B. (1991) Poloxamer 407 as an intraperitoneal barrier material for the prevention of postsurgical adhesion formation and reformation in rodent models for reproductive surgery, Obstet Gynecol, 77, 48-52.
162. Katakam, M., Ravis, W.R., Golden, D.L. & Banga, A.K. (1997) Controlled release of human growth hormone following subcutaneous administration in dogs. Int J Pharm, 152, 53-58.
163. Esposito, E., Carotta, Y., Scabbia, A., Trombelli, L., D'Antona, P., Menegatti, E. & Nastruzzi, C. (1996) Comparative analysis of tetracycline-containing dental gels: poloxamer-and monoglyceride-based formulations. Int J Pharm, 142, 9-23.
164. Bromberg, L. (1998) Novel family of thermogelling materials via C-C bonding between poly(acrylic acid) and poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide), J Phys Chem B, 102, 1956-1963.
165. Bromberg, L. (1998) Properties of aqueous solutions and gels of poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide)-g-poly(acrylic acid), J Phys Chem B, 102, 10736-10744.
166. Yuan, T., Palaniwasmy, R. Bromberg, L., Hatton, T.A. & Kam, C.T. (2007) Synthesis and aggregation behavior of Pluronic F87/poly(acrylic acid) block copolymer in the presence of doxorubicin, Langmuir, 23, 2638-2646.
167. Cleary, J., Bromberg, L.E. & Magner, E. (2003) Diffusion and release of solutes in Pluronic-g-poly(acrylic acid) hydrogels, Langmuir, 19, 9162-9172.
168. Barreiro-Iglesias, R., Bromberg, L., Temchenko, M., Hatton, T.A., Alvarez-Lorenzo, C. & Concheiro, A. (2005) Pluronic-g-poly(acrylic acid) copolymers as novel excipients for site specific, sustained release tablets. Eur J Pharm Sci, 26, 374-385.
169. Bromberg, L., Hatton, T.A., Barreiro-Iglesias, R., Alvarez-Lorenzo, C., Concheiro, A. (2007) Controlled release camptothecin tablets based on Pluronic and poly(acrylic acid) copolymer. Effect of fabrication technique on drug stability, tablet structure, and release mode, Drug Dev Ind Pharm, 33, 607-615.
170. Barreiro Iglesias, R., Bromberg, L., Temchenko, M., Hatton, T.A., Concheiro, A. & Alvarez-Lorenzo, C. (2004) Solubilization and stabilization of camptothecin in micellar solutions of pluronic-g-poly(acrylic acid) copolymers, J Control Rel, 97, 537-549.
171. Wen-Di, M., Hui, X., Chao, W., Shu-Fang, N. & Wei-San, P. (2008) Pluronic F127-gpoly(acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system, Int J Pharm, 350, 247-256.
172. Wen-di, M., Hui, X., Shu-fang, N. & Wei-san, P. (2008) Temperature-responsive, Pluronic-g-poly(acrylic acid) copolymers in situ gels for ophthalmic drug delivery: Rheology, in vitro drug release, and in vivo resident property, Drug Dev Ind Pharm, 34, 258-266.
173. Bromberg, L. & Temchenko, M. (1999) Self-Assembly in aqueous solutions of poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide)-b-poly(vinyl alcohol), Langmuir, 15, 8633-8639.
174. Bromberg, L. (2008) Polymeric micelles in oral chemotherapy, J Control Release, 128, 99-112.
175. Cohn, D., Sosnik, A. & Levy, A. (2003) Improved reverse thermo-responsive polymeric systems, Biomaterials, 24, 3707-3714.
176. Cohn, D., Sosnik, A., Malal, R., Zarka, R., Garty, S. & Levy A. (2007) Chain extension as a strategy for the development of improved reverse thermo-responsive polymers, Polym Adv Tech, 18, 731-736.
177. Cohn, D., Lando, G., Sosnik, A., Garty, S. & Levi, A. (2006) PEO-PPO-PEO based poly(ether ester urethane)s as degradable thermo-responsive multiblock copolymers, Biomaterials, 27, 1718-1727.
178. Sosnik, A., unpublished data.
179. Cohn, D. & Sosnik, A. (2003) Novel reverse thermo-responsive injectable poly(ether carbonate)s, J Mat Sci Mater Med, 14, 175-180.
180. Sosnik, A. & Cohn, D. (2005) Reverse thermo-responsive poly(ethylene oxide) and poly(propylene oxide) multiblock copolymers, Biomaterials, 26, 349-357.
181. Sosnik, A. (2002) PhD Thesis, Novel biodegradable injectable polymers for noninvasive surgery, The Hebrew University of Jerusalem.
182. Sosnik, A., Cohn, D., San Román, J. & Abraham, G.A. (2003) Crosslinkable PEOPPO-PEO-based reverse thermo-responsive gels as potentially injectable materials, J Biomater Sci Pol Edn, 14, 227-239.
183. Sosnik, A. & Cohn, D. (2004) Ethoxysilane-capped PEO-PPO-PEO triblocks: a new family of reverse thermo-responsive polymers, Biomaterials, 25, 2851-2858.
184. Cohn, D., Sosnik, A. & Garty, S. (2005) Smart hydrogels for in situ-generated implants, Biomacromolecules, 6, 1168-1175.
185. Sosnik, A., Leung, B., McGuigan, A.P. & Sefton M.V. (2005) Collagen/poloxamine hydrogels: Cytocompatibility of embedded HepG2 cells and surface attached endothelial cells, Tissue Eng, 11, 1807-16.
186. Sosnik, A., Leung, B.M. & Sefton, M.V. (2008) Lactoyl-poloxamine/collagen matrix for cell-containing modules, J Biomed Mater Res-A, 86, 339-353.
187. Cohn, D. & Sosnik, A. (2008) Responsive biomedical composites, U.S. Patent #7,425,322.
188. Cellesi, F., Tirelli, N. & Hubbell, J.A. (2004) Towards a fully-synthetic substitute of alginate: development of a new process using thermal gelation and chemical crosslinking, Biomaterials, 25, 5115-5124.
189. Park, S.Y., Chung, H.J., Lee, Y. & Park, T.G. (2008) Injectable and sustained delivery of human growth hormone using chemically modified Pluronic copolymer hydrogels, Biotech J, 3, 669-675.
190. Chung, H.J., Lee, Y. & Park, T.G. (2008) Thermo-sensitive and biodegradable hydrogels based on stereocomplexed Pluronic multi-block copolymers for controlled protein delivery, J Control Rel, 127, 22-30.
191. Mawad, D., Foster, J.L.J.R. & Lauto, A. (2008) Drug-delivery study and estimation of polymer-solvent interaction parameter for bisacrylate ester-modified Pluronic hydrogels, Int J Pharm, 360, 231-235.
192. Bromberg, L. & Alakhov, V. (2003) Effects of polyether-modified poly(acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers, J Control Rel, 88, 11-22.
193. Tian, Y., Bromberg, L., Lin, S.N., Hatton, T.A., & Tam, K.C. (2007) Complexation and release of doxorubicin from its complexes with pluronic P85-b-poly(acrylic acid) block copolymers, J Control Rel, 121, 137-145.
194. Tian,Y., Ravi, P., Bromberg, L., Hatton, T.A. & Tam, K.C. (2007) Synthesis and aggregation behavior of Pluronic F87/poly(acrylic acid) block copolymer in the presence of doxorubicin, Langmuir, 23, 2638-2646.
195. Belenkov, I., Alakhov, V.Y., Kabanov, A.V., Vinogradov, S.V., Panasci, L.C., Monia, B.P. & Chow, T.Y.K. (2004) Polyethyleneimine grafted with pluronic P85 enhances Ku86 antisense delivery and the ionizing radiation treatment efficacy in vivo, Gene Ther, 11, 1665-1672.
196. Murdan, S. (2005) A review of pluronic lecithin organogel as a topical and transdermal drug delivery system, Hosp Pharm, 12, 267-271.
197. Belgamwar, V.S., Pandey, M.S., Chauk, D.S. & Surana, S.J. (2008) Pluronic lecithin organogel, Asian J Pharm, 2, 134-138.
198. Burnham, R., Gregg, R., Healy, P. & Steadward, R. (1998) The effectiveness of topical diclofenac for lateral epicondylitis, Clin J Sports Med, 8, 78-81.
199. Paice, J., Von Roenn, J., Hudgins, J., Luong, L., Krejcie, T. & Avram, M. (2008) Morphine bioavailability from a topical gel formulation in volunteers, J Pain Symp Manag, 35, 314-320.
200. Steagall, P.V., Carnicelli, P., Taylor, P.M., Luna, S.P., Dixon, M. & Ferreira, T.H. (2006) Effects of subcutaneous methadone, morphine, buprenorphine or saline on thermal and pressure thresholds in cats, J Vet Pharmacol Ther, 29, 531-537.
201. Krotscheck, U., Boothe, D.M. & Boothe, H.W. (2004) Evaluation of transdermal morphine and fentanyl pluronic lecithin organogel administration in dogs, Vet Ther Res Appl Vet Med, 5, 202-211.
202. Richards, H., Thomas, C.P., Bowen, J.L. & Heard, C.M. (2006) In-vitro transcutaneous delivery of ketoprofen and polyunsaturated fatty acids from a pluronic lecithin organogel vehicle containing fish oil, J Pharm Pharmacol, 58, 903-908.
203. Loyd Jr, A. (1999) Piroxicam 0.5 percent in pluronic lecithin organogel, Int J Pharma Comp, 3, 133.
204. Grace, D., Rogers, J., Skeith, K. & Anderson, K. (1999) Topical diclofenac versus placebo: A double blind, randomized clinical trial in patients with osteoarthritis of the knee, J Rheumatol, 26, 2659-63.
205. Willis-Goulet, H.S., Schmidt, B.A., Nicklin, C.F., Marsella, R., Kunkle, G.A. & Tebbett, I.R. (2003) Comparison of serum dexamethasone concentrations in cats after oral or transdermal administration using pluronic lecithin organogel: A pilot study, Vet Dermatol, 14, 83-9.
206. Glisson, J.K., Wood, R.L, Kyle, P.B. & Cleary, J.D. (2005) Bioavailability of promethazine in a topical pluronic lecithin organogel: A pilot study, Int J Pharma Comp, 9, 242-246.
207. Giordano, J., Daleo, C. & Sacks, S.M. (1998) Topical ondansetron attenuates nociceptive and inflammatory effects of intradermal capsaicin in humans, Eur J Pharmacol, 354, 13-14.
208. Davidson, G. (2005) Update on transdermals for animal patients, Int J Pharma Comp, 9, 178-192.
209. Ciribassi, J., Luescher, A., Pasloske, K.S., Robertson-Plouch, C., Zimmerman, A. & Kaloostian-Whittymore, L. (2003) Comparative bioavailbility of fluoxetine after transdermal and oral administration to healthy cats, Am J Vet Res, 64, 994-998.
210. Hoffmann, G., Marks, S.L., Taboada, J., Hosgood-Pagel, G. & Wofsheimer K.L. (2003) Topical methimazole treatment in cats with hyperthyroidism, J Feline Med Surg, 5, 77-82.
211. Hoffman, S.B., Yoder, A.R. & Trepanier, L.A. (2002) Bioavailability of transdermal methimazole in a pluronic lecithin organogel in healthy cats, J Vet Pharmacol Ther, 25, 189-193.
212. Padilla, M., Clarck, G.T. & Merrill, R.L. (2000) Topical medications for orofacial neuropathic pain: A review, J Am Dent Assoc, 131, 184-195.
213. Toney, S. & King, E. (2001) Topically applied isophane insulin (NPH) in pluronic lecithin organogel, RxTriad-Literature watch, Int J Pharma Comp, September.
214. Sherman J. (2000) Droperidol 10 mg/mL for the treatment of severe nausea and vomiting, RxTriad-Literature watch, Int J Pharma Comp, September.
215. Mealy, K.L., Peck, K.E., Bennett, B.S., Sellon, R.K. & Swinney, G.R., Melzer, K. (2004) Systemic absorption of amitriptyline and buspirone after oral and transdermal administration to healthy cats, J Vet Int Med, 18, 43-46.
216. Alvarez-Lorenzo, C., Bromberg, L. and Concheiro, A. (2009) Light-sensitive intelligent drug delivery systems, Photochem Photobiol, 85, 848-860.
217. Alvarez-Lorenzo,C., Deshmukh, S., Bromberg, L., Hatton, T.A., Sández-Macho, I. & Concheiro, A. (2007) Temperature-and light-responsive blends of Pluronic F127 and poly(N,N-dimethylacrylamide-co-methacryloyloxyazobenzene), Langmuir, 23, 11475-11481.
218. Westerink, M.A.J., Smithson, S.L., Srivastava, N., Blonder, J., Coeshott, C., & Rosenthal, G.J. (2001) ProJuvant™ (Pluronic F127®/chitosan) enhances the immune response to intranasally administered tetanus toxoid, Vaccine, 20, 711-723.
219. Kim, M.R. & Park, T.G. (2002) Temperature-responsive and degradable hyaluronic acid/Pluronic composite hydrogels for controlled release of human growth hormone, J Control Rel, 80, 69-77.
220. Chun, K.W., Lee, J.B., Kim, S.H., Park, T.G. (2005) Controlled release of plasmid DNA from photo-cross-linked pluronic hydrogels, Biomaterials, 26, 3319-3326.
221. Yoon, J.J., Chung, H.J. & Park, T.G. (2007) Photo-crosslinkable and biodegradable Pluronic/heparin hydrogels for local and sustained delivery of angiogenic growth factor, J Biomed Mater Res A, 83, 597-605.
222. Lin, H.-R., Sung, K.C. & Vong, W.-J. (2004) In situ gelling of alginate/Pluronic solutions for ophthalmic delivery of pilocarpine, Biomacromolecules, 5, 2358-2365.
223. Oh, K.S., Han, S.K., Choi, Y.W., Lee, J.H., Lee, J.Y., & Yuk, S.H. (2004) Hydrogenbonded polymer gel and its application as a temperature-sensitive drug delivery system, Biomaterials, 25, 2393-2398.
224. Majithiya, R.J., Ghosh, P.K., Umrethia, M.L. & Murthy R.S.R. (2006) Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan, AAPS PharmSciTech, 7, Art. 67.
225. Kao, H.-J.Huei-Jen, Lo, Y.-L., Vong, W.-J., Lin, Y.-J. & Lin, H.-R. (2006) Treating allergic conjunctivitis using in situ polyelectrolyte gelling systems, J Biomater Sci Polym Edn, 17, 1191-1205.
226. Gupta, H., Jain, S., Mathur, R., Mishra, P., Mishra, A.K. & Velpandian, T. (2007) Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system, Drug Del, 14, 507-515.
227. Park, H.Y., Oh, K.S., Koo, H.M., Cho, S.H., Chung, S.J., Lim, Y.T., Kim, D. & Yuk, S.H. (2008) Heparin-immobilized pluronic/PVA composite microparticles for the sustained delivery of ionic drug, J Microencap, 25, 106-110.